Good Saturday morning to all my $AMRN friends out there who have nothing better to do. So while you're here let me give you my wild-ass (maybe not so wild-ass), VASCEPA sales projections through 2029 (TEVA Entrance H2). I've said for a long time that I believe VASCEPA Peak Sales will exceed those of Lipitor in 2006 ($12.9B). I'm therefore projecting VASCEPA to hit Peak Sales of nearly $20B at the end of 2024 ($19.8B.) In this projection I'm assuming all patents expire about 2030. I believe many new IP's will be developed including V2.0 and new indications that will extend VASCEPA for the next 50-75 years. Your grandchildren and great grandchildren will be telling their friends what a genius you were!